Using a mouse model, scientists from the RIKEN-Max Planck Joint Research Center for Systems Chemical Biology and a number of other institutes have identified a sugar molecule that reduced the inflammatory response and progress of emphysema, a common component of chronic obstructive pulmonary disease (COPD). According to Naoyuki Taniguchi, the leader of the group, this discovery could lead to the development of drugs based on glycans—biological sugar molecules—for the treatment of diseases such as COPD, which is the fourth leading cause of death worldwide.
As part of the research group’s work to explore the roles of sugar molecules in health and disease, they found that keratan sulfate, a large negatively charged saccharide found in the small airway of the lung, is decreased in mice that have been exposed to cigarette smoke. They wondered if this decrease might be associated with the damage that smoking causes to the lung. Taniguchi says, “We are not absolutely sure of the mechanism through which smoking leads to a reduction in keratan sulfate, but felt that clearly the reduction is important in thinking about glycan-based strategies for combating emphysema and COPD.”
They wondered whether the keratan sulfate might be playing a protective role in COPD. To test the hypothesis, they prepared a repeating disaccharide element of keratan sulfate, named L4, and administered it into two mouse models of emphysema—one a model of emphysema triggered by the enzyme elastase, and the other an exacerbation of smoking-induced emphysema triggered by LPS, a toxin found in bacterial cell walls.
In the first model, they found that that treatment with L4 prevented destruction of the alveoli—the small air sacs in lungs that are used to exchange gases, and in addition that it reduced the infiltration of a type of white blood cell called neutrophils, which is symptomatic of an inflammatory response, as well as levels of inflammatory cytokines and tissue-degrading enzymes. Although L4 was shown to inhibit these enzymes, they did not find any ability of L4 to directly reduce the production of cytokines or reactive oxygen species, so concluded that the action was also being done indirectly, through mechanisms involving the neutrophils.
In the exacerbation model, they found that the L4 administration prevented the influx of neutrophils. According to Taniguchi, “We found that L4 was as effective as dexamethasone in reducing neutrophil infiltration. This is very exciting, because dexamethasone, the treatment currently used for COPD, is a steroid medication that can have serious side effects and can in some cases make the outcome worse. It will be exciting if we can show that L4—a sugar molecule which we found had no adverse effects in the mice even at high doses—can be used as a treatment for this condition, which exerts a tremendous health burden.”
According to Taniguchi, there is still work to be done in the area. “We plan now to try to determine exactly how L4 blocks neutrophil migration, by finding a target receptor protein, and how L4 can suppress inflammation in vivo, as this could give us important insights into the mechanism of COPD progression and how it can be halted.”
Receive an email update when we add a new COPD article.
The Latest on: COPD
via Google News
The Latest on: COPD
- Asthma and COPD Drug Market 2019: Global Key Players, Trends, Share, Industry Size, Segmentation, Opportunities, Forecast To 2026on November 17, 2019 at 11:17 pm
COPD drugs and Asthma are considered to be one of the foremost leading medicine in the contemporary health – medicine market. Asthma has always been a common disease among smokers, and the ratio is ...
- Lifestyle choices have effect on COPDon November 17, 2019 at 9:06 pm
Patients with COPD suffer from progressive shortness of breath, coughing, wheezing and sputum production. Most patients with emphysema have been cigarette smokers. Patients with emphysema develop ...
- Study Results Call for Attention to Sex Differences in COPDon November 16, 2019 at 5:09 am
Clinical characteristics of women with chronic obstructive pulmonary disease (COPD) are important for primary care clinicians to consider in order to improve COPD awareness since women often go ...
- Ted Koppel and his wife have dedicated themselves to fighting COPDon November 15, 2019 at 3:57 am
In 2001, a doctor diagnosed Grace Anne Dorney Koppel with chronic obstructive pulmonary disease, or COPD, telling her she had just three to five years left to live. © Courtesy Stanford Medicine Ted ...
- When Ted Koppel's wife was given a few years left to live, the couple dedicated themselves to fighting COPDon November 15, 2019 at 3:57 am
(CNN)In 2001, a doctor diagnosed Grace Anne Dorney Koppel with chronic obstructive pulmonary disease, or COPD, telling her she had just three to five years left to live. She and her husband, long-time ...
- COPD: New Diagnostic Criteria Proposedon November 13, 2019 at 10:36 am
New criteria for diagnosing chronic obstructive pulmonary disease (COPD) have been published by researchers at National Jewish Health. COPD is the fourth leading cause of death in the United States.
- Fifth Season Financial Offers Resources for COPD Patients Facing Financial Hardshipon November 13, 2019 at 8:27 am
STAMFORD, Conn., Nov. 13, 2019 /PRNewswire/ -- November 13, 2019 /PRNewswire/ -- According to the Centers for Disease Control and Prevention (CDC), chronic obstructive pulmonary disease (COPD) affects ...
- COPD Drugs Market 2019 Global Demands and Precise Outlook - Chiesi Pharmaceuticals, Novartis, Merck, Cipla, Mylan, Vectura, Sunovionon November 10, 2019 at 10:33 pm
Nov 11, 2019 (Market Insight Reports via COMTEX) -- The report titled "Global COPD Drugs Market: Analysis By Drug Type (Combination Therapy Drugs, Anticholinergics, Beta-Agonist, Inhaled ...
- Grifols introduces AlphaID™, a free cheek swab to screen for Alpha-1, the most common genetic form of COPDon November 8, 2019 at 5:26 am
"AlphaID™ is an innovative, convenient way for patients to be screened for Alpha-1, which could mean earlier diagnosis and management of COPD," said Angela Davis, M.D., Global Medical Director ...
via Bing News